APA (7th ed.) Citation

F, M., M, H., N, M., H, F., VM, R., U, J., . . . M, K. (2025). The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study. Cancers, 17(13), . https://doi.org/10.3390/cancers17132190

Chicago Style (17th ed.) Citation

F, Marković, Hochmair M, Müser N, Fabikan H, Rodriguez VM, Janzic U, Stjepanović M, and Kontić M. "The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study." Cancers 17, no. 13 (2025). https://doi.org/10.3390/cancers17132190.

MLA (9th ed.) Citation

F, Marković, et al. "The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study." Cancers, vol. 17, no. 13, 2025, https://doi.org/10.3390/cancers17132190.